Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | LTA4H | P09960 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | HRH2 | P25021 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1623579 | 0.92 | BRD4 (0.54) | MAPTLTA4HHRH2HRH1 | |
| SCHEMBL1285034 | 0.90 | LTA4H (0.53) | MAPTLTA4HHRH2HRH1ALDH1A1 | |
| SCHEMBL1285180 | 0.89 | LTA4H (0.52) | MAPTLTA4HHRH2HRH1 | |
| SCHEMBL1284955 | 0.89 | LTA4H (0.52) | MAPTLTA4HHRH2HRH1 | |
| SCHEMBL1286274 | 0.88 | HRH2 (0.58) | MAPTLTA4HHRH2HRH1 | |
| SCHEMBL3951838 | 0.86 | L3MBTL1 (0.66) | LTA4HL3MBTL1TSHRPOLBKMT2A | |
| SCHEMBL21992555 | 0.85 | MAPT (0.60) | MAPTLTA4HPOLBALDH1A1HPGD | |
| SCHEMBL7692039 | 0.85 | LTA4H (0.52) | MAPTLTA4HL3MBTL1TSHRPOLB | |
| SCHEMBL7692040 | 0.85 | LTA4H (0.52) | LTA4HL3MBTL1TSHRPOLBKMT2A | |
| SCHEMBL28532238 | 0.84 | NPSR1 (0.51) | MAPTHRH2HRH1KMT2AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | MAPT 4264/4885LTA4H 99/4885L3MBTL1 1170/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | MAPT 4264/4885LTA4H 99/4885L3MBTL1 1170/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | MAPT 4264/4885LTA4H 99/4885L3MBTL1 1170/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | MAPT 4264/4885LTA4H 99/4885L3MBTL1 1170/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | MAPT 4264/4885LTA4H 99/4885L3MBTL1 1170/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | MAPT 4264/4885LTA4H 99/4885L3MBTL1 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.